Auro Vaccines LLC
Auro Vaccines LLC is a clinical-stage vaccine development company pioneering a major evolutionary step in the design and development of preventive and therapeutic vaccines for infectious diseases. They focus on tailoring immune responses to specific targets using their proprietary PBS Vax™ platform, aiming to address unmet medical needs in chronic viral diseases, emerging infectious diseases, and cancers. Their innovative platform enables the development of vaccines for diseases such as Ebola, Marburg, Nipah, Lassa, HIV, HPV, HBV, HCV, HSV-2, and RSV, among others. The company collaborates with various organizations and has a growing pipeline of vaccine candidates, including prophylactic and therapeutic vaccines, with several in clinical or preclinical stages.
Industries
Nr. of Employees
small (1-50)
Auro Vaccines LLC
Bldg. 205, R 304, 401 North Middletown Rd., Pearl River, NY 10965
Products
Subunit vaccine for Nipah/Hendra (envelope glycoprotein)
A subunit vaccine composed of the Hendra/Nipah envelope glycoprotein, advanced through small‑animal immunogenicity and IND‑enabling safety studies and undergoing Phase 1 clinical evaluation.
Vesiculovirus‑vectored filovirus vaccine franchise (Ebola, Marburg)
Replication‑competent vesiculovirus-vectored vaccines demonstrating single‑dose protection in non-human primate challenge studies; programs have been out‑licensed for further clinical development.
Prophylactic candidate vaccines for SARS‑CoV‑2 and Chikungunya
Vaccine candidates employing vesiculovirus vectors or prime/boost strategies poised to enter clinical evaluation for prevention of SARS‑CoV‑2 and Chikungunya virus infection.
Therapeutic HPV vaccine (DNA prime / viral boost)
A multi‑valent therapeutic vaccine designed to treat HPV-associated cervical and head & neck disease as an adjunct to surgery; lead design completed and candidate prepared for cGMP manufacture and anticipated clinical testing.
Therapeutic vaccine candidates for HBV, HCV and HSV‑2
Prime/boost therapeutic vaccine development programs targeting multiple genotypes of HBV and HCV and an antigen-discovery stage HSV‑2 candidate intended to be used alongside drug therapy.
Subunit vaccine for Nipah/Hendra (envelope glycoprotein)
A subunit vaccine composed of the Hendra/Nipah envelope glycoprotein, advanced through small‑animal immunogenicity and IND‑enabling safety studies and undergoing Phase 1 clinical evaluation.
Vesiculovirus‑vectored filovirus vaccine franchise (Ebola, Marburg)
Replication‑competent vesiculovirus-vectored vaccines demonstrating single‑dose protection in non-human primate challenge studies; programs have been out‑licensed for further clinical development.
Prophylactic candidate vaccines for SARS‑CoV‑2 and Chikungunya
Vaccine candidates employing vesiculovirus vectors or prime/boost strategies poised to enter clinical evaluation for prevention of SARS‑CoV‑2 and Chikungunya virus infection.
Therapeutic HPV vaccine (DNA prime / viral boost)
A multi‑valent therapeutic vaccine designed to treat HPV-associated cervical and head & neck disease as an adjunct to surgery; lead design completed and candidate prepared for cGMP manufacture and anticipated clinical testing.
Therapeutic vaccine candidates for HBV, HCV and HSV‑2
Prime/boost therapeutic vaccine development programs targeting multiple genotypes of HBV and HCV and an antigen-discovery stage HSV‑2 candidate intended to be used alongside drug therapy.
Services
Collaborative application of the prime/boost platform with pharmaceutical, biotech and public‑health partners to develop prophylactic and therapeutic vaccines.
Licensing or sublicensing of vaccine candidates and platform IP to third parties for further clinical development and commercialization.
Support for preclinical efficacy/toxicology programs and coordinated multi-site clinical trials to evaluate safety and immunogenicity.
Upstream and downstream process development and coordination with contract manufacturers for cGMP production and lot release of viral‑vectored vaccines.
Collaborative application of the prime/boost platform with pharmaceutical, biotech and public‑health partners to develop prophylactic and therapeutic vaccines.
Licensing or sublicensing of vaccine candidates and platform IP to third parties for further clinical development and commercialization.
Support for preclinical efficacy/toxicology programs and coordinated multi-site clinical trials to evaluate safety and immunogenicity.
Upstream and downstream process development and coordination with contract manufacturers for cGMP production and lot release of viral‑vectored vaccines.
Expertise Areas
- Vaccine platform development (prime/boost strategies)
- Viral‑vectored vaccine development
- Plasmid DNA vaccine design and delivery
- Preclinical efficacy and animal challenge models
Key Technologies
- Plasmid DNA vaccines (pDNA)
- Electroporation-mediated DNA delivery
- Replication-competent vesiculovirus vectors (e.g., rVSV, Isfahan)
- Plasmid-expressed molecular adjuvants (IL-12)